Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
ACS Management NSTEMI Pro DTI “Hook-ster Hoekstra” Pro Factor Xa “Knockdown Diercks”
Gregg W. Stone MD for the ACUITY Investigators
Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl, Frederick Feit, Antonio.
Harvard Medical School Cost-Effectiveness in Acute Coronary Syndromes The ACUITY Economic Study David J. Cohen, M.D., M.Sc. on behalf of the ACUITY Investigators.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
Roxana Mehran, on behalf of the ACUITY investigators
